ERBB2 and breast cancer: Several clinical trials proved that about 25–30% of HER2+ BC patients, treated with trastuzumab, after adjuvant chemotherapy experienced recurrence within 10 years of diagnosis5,10 and locoregional or distant recurrence has been identified after dual HER2-targeted neoadjuvant treatment (about 7.1% of cases)11.